Search Results

2,014 Results for "ipsen".

Sort By

Rare diseases

Regeneron wins FDA approval to challenge Ipsen for rare bone disease market

Regeneron’s Pasatru is the second fibrodysplasia ossificans progressiva drug approved in the U.S., following the 2023 approval of Ipsen’s Sohonos.

August 20, 2026
·
2 min read
·
Nick Paul Taylor
Mergers & acquisitions

Ipsen makes up to $1.75B blood cancer bet with Kartos buyout

The star of Ipsen’s acquisition is an MDM2 blocker being proposed as an add-on therapy to ruxolitinib for myelofibrosis. The drug could be available to patients “as early as 2028,” according to Ipsen CEO David Loew.

June 29, 2026
·
2 min read
·
Tristan Manalac
Deals

Ipsen sends clear Memo to rare diseases with up to $796M buyout

Ipsen is penning its second acquisition of the week, this time securing Memo Therapeutics and its midstage monoclonal antibody in a deal that could approach $800 million.

July 1, 2026
·
2 min read
·
Gabrielle Masson
Press Releases

Ipsen appoints Mariette Finet to its Board of Directors

September 18, 2026
·
6 min read
Press Releases

IPSEN - Buy-back programme - Art 5 of MAR - Week 39 - 2026

September 28, 2026
·
1 min read
Press Releases

IPSEN - Buy-back programme - Art 5 of MAR - Week 38 - 2026

September 23, 2026
·
1 min read
Press Releases

Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset to Ipsen’s Rare Disease pipeline

July 22, 2026
·
7 min read
Press Releases

IPSEN - Buy-back programme - Art 5 of MAR - Week 37 - 2026

September 14, 2026
·
1 min read
Press Releases

Ipsen completes acquisition of Kartos Therapeutics, strengthening late-stage Oncology pipeline

August 21, 2026
·
6 min read
Cancer

Ipsen Pulls Cancer Drug Amid Risk of Secondary Malignancies

Ipsen will withdraw Tazverik’s follicular lymphoma and epithelioid sarcoma indications as emerging data point to an elevated safety risk in patients undergoing treatment.

March 9, 2026
·
2 min read
·
Tristan Manalac